Abstract Use of Direct Oral Anticoagulants (DOACs) is continuously increasing for clinical
application. The first product released was Dabigatran, which was proposed for many …

Background Dabigatran is an oral direct thrombin inhibitor for which routine laboratory
monitoring is currently not recommended. However, there are situations in which …

Introduction Several specific assays are commercially available to determine dabigatran
anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five …

The direct oral anticoagulant dabigatran does not require therapeutic drug monitoring,
however emergency measurements are gaining importance. Current assays feature good …

Background Direct oral anticoagulants (DOACs) are increasingly replacing vitamin K
antagonists (VKA) for clinical indications requiring long-term oral anticoagulation. In contrast …

Ways to monitor dabigatran etexilate (DE) therapy would be useful in certain situations.
Functional assays such as aPTT or Hemoclot® Thrombin Inhibitor (HTI) have been …

Background Issues with laboratory measurement of dabigatran include: 1. Do coagulation
assays reflect dabigatran plasma concentrations? 2. Do samples from patients treated with …

Background: Dabigatran etexilate is a new oral anticoagulant for the therapy and
prophylaxis of venous thromboembolism and stroke prevention in patients with atrial …

Objectives: To study dabigatran etexilate, a new oral anticoagulant that functions as a direct
thrombin inhibitor. Methods: This study evaluates four methods, one of which is performed in …

Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may
be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of …